Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR.

Borgatti A, Koopmeiners JS, Sarver AL, Winter AL, Stuebner K, Todhunter D, Rizzardi AE, Henriksen JC, Schmechel S, Forster CL, Kim JH, Froelich J, Walz J, Henson MS, Breen M, Lindblad-Toh K, Oh F, Pilbeam K, Modiano JF, Vallera DA

Mol. Cancer Ther. 16 (5) 956-965 [2017-05-00; online 2017-02-13]

Sarcomas differ from carcinomas in their mesenchymal origin. Therapeutic advancements have come slowly, so alternative drugs and models are urgently needed. These studies report a new drug for sarcomas that simultaneously targets both tumor and tumor neovasculature. eBAT is a bispecific angiotoxin consisting of truncated, deimmunized

Affiliated researcher

PubMed 28193671

DOI 10.1158/1535-7163.MCT-16-0637

Crossref 10.1158/1535-7163.MCT-16-0637

pii: 1535-7163.MCT-16-0637
pmc: PMC5418099
mid: NIHMS849663


Publications 7.1.2